E-ISSN 2231-3206 | ISSN 2320-4672
 

Original Research 


Pharmacokinetics of injectable beta-cyclodextrin-oridonin inclusion complex, a novel formulation of oridonin in Wistar rats

Bqoqu Li, Na Li, Shujuan Wang.

Cited by (1)

Abstract
Aim:Oridonin is a new anti-tumor drug candidate with promising antitumor activity. The aim of the present study is to investigate the single- and repeated-dose pharmacokinetics of injectable beta-cyclodextrin-oridonin inclusion complex in rats. Methods: Rats were given single- or multiple-dose (7 days) of injectable beta-cyclodextrin-oridonin inclusion complex (single-dose: 33 mg/m2, 99 mg/m2, 296 mg/m2; repeatede-dose: 99 mg/m2 calculated as oridonin) by intravenous injection. Plasma oridonin was analyzed by LC–ESI-MS. The main pharmacokinetics parameters were calculated and compared. Results: The PK data of single-dose injectable beta-cyclodextrin-oridonin inclusion complex in rats were best fit by a three-compartment model.The terminal elimination half-life (t1/2z) of oridonin ranged from 8.72±1.14 to 10.87±2.03h. AUC (0-t) and Cmax for oridonin showed statistically significant differences (p < 0.05) between singledose and repeated dose. Conclusion: Our study has led to the view that injectable beta-cyclodextrin-oridonin inclusion complex can increase the bioavailability of oridonin in rats and is suitable for once a day dosing. However, caution should be taken when injectable beta-cyclodextrin-oridonin inclusion complex is given by i.v. repeatedly.

Key words: Pharmacokinetics; Oridonin; Beta-cyclodextrin; rats


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Bqoqu Li
Articles by Na Li
Articles by Shujuan Wang
on Google
on Google Scholar

This Article Cited By the following articles

Trends of articles published in National Journal of Physiology, Pharmacy and Pharmacology NJPPP
National Journal of Physiology, Pharmacy and Pharmacology 2013; 3(2): 102.

1
 
How to Cite this Article
Pubmed Style

Bqoqu Li, Na Li, Shujuan Wang. Pharmacokinetics of injectable beta-cyclodextrin-oridonin inclusion complex, a novel formulation of oridonin in Wistar rats. Natl J Physiol Pharm Pharmacol. 2012; 2(1): 52-57.


Web Style

Bqoqu Li, Na Li, Shujuan Wang. Pharmacokinetics of injectable beta-cyclodextrin-oridonin inclusion complex, a novel formulation of oridonin in Wistar rats. https://www.njppp.com/?mno=9541 [Access: August 03, 2022].


AMA (American Medical Association) Style

Bqoqu Li, Na Li, Shujuan Wang. Pharmacokinetics of injectable beta-cyclodextrin-oridonin inclusion complex, a novel formulation of oridonin in Wistar rats. Natl J Physiol Pharm Pharmacol. 2012; 2(1): 52-57.



Vancouver/ICMJE Style

Bqoqu Li, Na Li, Shujuan Wang. Pharmacokinetics of injectable beta-cyclodextrin-oridonin inclusion complex, a novel formulation of oridonin in Wistar rats. Natl J Physiol Pharm Pharmacol. (2012), [cited August 03, 2022]; 2(1): 52-57.



Harvard Style

Bqoqu Li, Na Li, Shujuan Wang (2012) Pharmacokinetics of injectable beta-cyclodextrin-oridonin inclusion complex, a novel formulation of oridonin in Wistar rats. Natl J Physiol Pharm Pharmacol, 2 (1), 52-57.



Turabian Style

Bqoqu Li, Na Li, Shujuan Wang. 2012. Pharmacokinetics of injectable beta-cyclodextrin-oridonin inclusion complex, a novel formulation of oridonin in Wistar rats. National Journal of Physiology, Pharmacy and Pharmacology, 2 (1), 52-57.



Chicago Style

Bqoqu Li, Na Li, Shujuan Wang. "Pharmacokinetics of injectable beta-cyclodextrin-oridonin inclusion complex, a novel formulation of oridonin in Wistar rats." National Journal of Physiology, Pharmacy and Pharmacology 2 (2012), 52-57.



MLA (The Modern Language Association) Style

Bqoqu Li, Na Li, Shujuan Wang. "Pharmacokinetics of injectable beta-cyclodextrin-oridonin inclusion complex, a novel formulation of oridonin in Wistar rats." National Journal of Physiology, Pharmacy and Pharmacology 2.1 (2012), 52-57. Print.



APA (American Psychological Association) Style

Bqoqu Li, Na Li, Shujuan Wang (2012) Pharmacokinetics of injectable beta-cyclodextrin-oridonin inclusion complex, a novel formulation of oridonin in Wistar rats. National Journal of Physiology, Pharmacy and Pharmacology, 2 (1), 52-57.